| Followers | 35 |
| Posts | 1912 |
| Boards Moderated | 0 |
| Alias Born | 11/05/2020 |
Monday, February 02, 2026 11:19:11 AM
"Rotation." A mighty fine way to put it. It's exactly how it works in the OTC.
(a). If we don't get approval or there is no substantial news.... "FDA is corrupt."
(b). If the stock price goes down and won't move up on any PR....... "market makers are keeping this down."
(c). If the "CEO" doesn't bring something up...... "he can't talk about it right now."
Only in the OTC do we have this kind of circus.
The fact is there is no full research paper from Krimins. A very peculiar situation. But not one that is totally surprising. I want to see exactly the mathematical equation(s) they used and all their procedural data. Yet, it is conveniently missing.
What we have instead is an abstract that highlights what appears at first glance to be "a medical device that does its intended purpose."
And that's just it; in the realm of science research this is perfectly acceptable. That's what research can do - take a single variable experiment and result it as a "positive" outcome. No matter how "junk" science it really is.
However, in the real world, we know this isn't applicable. And so doesn't the FDA.
It's another one of those "we will give you information but not the whole story." And like usual the "shareholder" base believes whatever they write.
(a). If we don't get approval or there is no substantial news.... "FDA is corrupt."
(b). If the stock price goes down and won't move up on any PR....... "market makers are keeping this down."
(c). If the "CEO" doesn't bring something up...... "he can't talk about it right now."
Only in the OTC do we have this kind of circus.
The fact is there is no full research paper from Krimins. A very peculiar situation. But not one that is totally surprising. I want to see exactly the mathematical equation(s) they used and all their procedural data. Yet, it is conveniently missing.
What we have instead is an abstract that highlights what appears at first glance to be "a medical device that does its intended purpose."
And that's just it; in the realm of science research this is perfectly acceptable. That's what research can do - take a single variable experiment and result it as a "positive" outcome. No matter how "junk" science it really is.
However, in the real world, we know this isn't applicable. And so doesn't the FDA.
It's another one of those "we will give you information but not the whole story." And like usual the "shareholder" base believes whatever they write.
Recent RDGL News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:44:48 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 03/06/2026 05:15:04 AM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 03/04/2026 04:48:52 PM
- Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites • GlobeNewswire Inc. • 02/17/2026 01:30:00 PM
- Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™ • GlobeNewswire Inc. • 02/10/2026 01:30:00 PM
- Vivos Inc Updates Human Therapy Progress in India • GlobeNewswire Inc. • 02/03/2026 01:30:00 PM
- Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals • GlobeNewswire Inc. • 01/28/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2026 04:06:21 PM
- Vivos Inc Summarizes Progress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 05:56:08 PM
- Vivos Inc Summarzes Preogress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2025 09:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2025 12:34:42 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:08:03 AM
- Vivos Inc. Issues Shareholder Update Letter • GlobeNewswire Inc. • 11/06/2025 01:30:00 PM
- Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics • GlobeNewswire Inc. • 10/29/2025 12:30:00 PM
- Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel® • GlobeNewswire Inc. • 10/27/2025 12:30:00 PM
- Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 05:46:00 PM
- Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:01:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 07:32:46 PM
